Frazier Life Sciences Public Fund, L.P. - 31 Mar 2025 SCHEDULE 13G/A Report for Savara Inc. Common Stock, par value $0.001 per share (SVRA)

Filing manager
Frazier Life Sciences Public Fund, L.P.
Reporting owner
James N. Topper
Security
Savara Inc. Common Stock, par value $0.001 per share
Beneficially owned shares
11,462,301 shares
Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13G/A

Passive or exempt beneficial ownership filing.

Ownership

6.6%

Beneficial ownership of this reported class.

Shares

11,462,301 shares

Shares beneficially owned as disclosed.

Event date

31 Mar 2025

Date tied to the ownership event or amendment.

Accepted by SEC

15 May 2025

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Class ownership
6.6%
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
SVRA
Shares outstanding
173,671,227 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13G/A
Accepted by SEC
15 May 2025, 09:52:48 UTC
Event date
31 Mar 2025
Next SEC filing
14 Aug 2025
Source filing
View source filing

Key filing fact

Frazier Life Sciences Public Fund, L.P. disclosed 6.6% ownership in Savara Inc. Common Stock, par value $0.001 per share (SVRA) on 31 Mar 2025.

Key facts

  • Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G/A for Savara Inc. Common Stock, par value $0.001 per share (SVRA).
  • Disclosed ownership: 6.6%.
  • Date of event: 31 Mar 2025.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 15 May 2025, 09:52.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (17)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
Frazier Life Sciences Public Fund, L.P. 3.9% 6,745,296 0 6,745,296 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
FHMLSP, L.P. 3.9% 6,745,296 0 6,745,296 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
FHMLSP, L.L.C. 3.9% 6,745,296 0 6,745,296 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. 1.7% 2,889,469 0 2,889,469 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
FHMLSP Overage, L.P. 1.7% 2,889,469 0 2,889,469 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C. 1.7% 2,889,469 0 2,889,469 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Frazier Life Sciences X, L.P. 0.2% 324,346 0 324,346 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
FHMLS X, L.P. 0.2% 324,346 0 324,346 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
FHMLS X, L.L.C. 0.2% 324,346 0 324,346 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. 0.9% 1,503,190 0 1,503,190 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
FHMLS XI, L.P. 0.9% 1,503,190 0 1,503,190 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
FHMLS XI, L.L.C. 0.9% 1,503,190 0 1,503,190 /s/ Steve R. Bailey By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
James N. Topper 6.6% 11,462,301 0 11,462,301 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Patrick J. Heron 6.6% 11,462,301 0 11,462,301 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Albert Cha 5.6% 9,634,765 0 9,634,765 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
James Brush 5.6% 9,634,765 0 9,634,765 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Daniel Estes 0.9% 1,503,190 0 1,503,190 /s/ Steve R. Bailey By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .